Why I Stopped Being A “Good” Cancer Patient
“You are allergic to your oral chemotherapy,” explains my oncology team at a recent appointment. “We are going to try a newer drug,” I am on my fourth attempt to find an oral treatment suitable for both my body and my cancer, so that I can maintain a remission that took three years and a stem cell transplant to achieve. “We want to get ahead of it before it gets ahead of us.” In my headphones, Weezer achingly croons, “Say it ain’t so, your drug is a heartbreaker.” [time-brightcove not-tgx=”true”] Since being diagnosed with phase three chronic myeloid leu...
Source: TIME: Health - February 6, 2024 Category: Consumer Health News Authors: Walela Nehanda Tags: Uncategorized freelance Source Type: news

All-Oral Therapy Promising in Higher-Risk MDS, CMML
(MedPage Today) -- An all-oral combination therapy appeared to show promising activity for patients with higher-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML), with acceptable safety, according to results from a... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - February 5, 2024 Category: Hematology Source Type: news

Chronic Lymphocytic Leukemia Highlights From ASH 2023 Chronic Lymphocytic Leukemia Highlights From ASH 2023
Doublet and triplet therapies as well as strong results from late-generation BTK inhibitors and sequencing are among CLL highlights from ASH 2023, as reported by Dr John Allan.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 27, 2023 Category: Consumer Health News Tags: Hematology-Oncology ReCAP Source Type: news

FDA Approves Label Update for Brukinsa (zanubrutinib) in Chronic Lymphocytic Leukemia (CLL)
U.S. label update includes superior progression-free survival results from the Phase 3 ALPINE head-to-head trial of Brukinsa versus Imbruvica® (ibrutinib) in Relapsed or Refractory CLL ALPINE is the only Phase 3 Bruton’s tyrosine kinase... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 22, 2023 Category: Drugs & Pharmacology Source Type: news

ASH: MRD-Directed Ibrutinib-Venetoclax Treatment Beneficial in Leukemia
WEDNESDAY, Dec. 13, 2023 -- For patients with chronic lymphocytic leukemia (CLL), measurable residual disease (MRD)-directed ibrutinib-venetoclax treatment improves progression-free and overall survival, according to a study published online Dec.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 13, 2023 Category: Pharmaceuticals Source Type: news

Measurable Residual Disease-Guided Therapy Promising in CLL Measurable Residual Disease-Guided Therapy Promising in CLL
The ibrutinib-venetoclax combination was particularly effective in patients with chronic lymphocytic leukemia with high-risk features such as IGHV unmutated disease or chromosomal abnormalities.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 12, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news

'New Gold Standard' for Previously Untreated CLL
(MedPage Today) -- SAN DIEGO -- A time-limited, targeted combination significantly improved survival compared with chemoimmunotherapy in fit chronic lymphocytic leukemia (CLL) patients who met criteria for starting treatment, findings from the... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - December 10, 2023 Category: Hematology Source Type: news

Frontline Venetoclax-Ibrutinib for CLL Boosts Survival in Fit Patients
(MedPage Today) -- SAN DIEGO -- A time-limited, targeted combination significantly improved survival compared with chemoimmunotherapy in fit chronic lymphocytic leukemia (CLL) patients who met criteria for starting treatment, findings from the... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - December 10, 2023 Category: Hematology Source Type: news

Non-Covalent BTK Inhibitor Approved for CLL
(MedPage Today) -- The FDA expanded the label of pirtobrutinib (Jaypirca) to include the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) following two prior lines of therapy, the agency announced on Friday. An... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - December 4, 2023 Category: Hematology Source Type: news

Jaypirca (pirtobrutinib) Now Approved by U.S. FDA for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Have Received at Least Two Lines of Therapy, Including a BTK Inhibitor and a BCL-2 Inhibitor
The first and only non-covalent (reversible) BTK inhibitor, Jaypirca has been shown to extend the benefit of BTK inhibition In the BRUIN Phase 1/2 trial, adult patients with CLL/SLL who have received at least two lines of therapy, including a BTK... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 1, 2023 Category: Drugs & Pharmacology Source Type: news

First in human trial of new drug raises hopes for patients with relapsed blood cancer
A new targeted drug, studied by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James), may offer a new treatment option for patients with blood cancers, including chronic lymphocytic leukemia (CLL) and Non-Hodgkin lymphoma (NHL) whose disease has stopped responding to standard treatments. (Source: World Pharma News)
Source: World Pharma News - November 6, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Roche to present new data at ASH 2023 showcasing breadth of haematology portfolio spanning 10 different types of blood disorders
Basel, 2 November 2023 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today it will be presenting more than 45 abstracts at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, spanning 10 haematology indications.New data reflect Roche ’s commitment to advancing treatment standards even further to help improve the lives of people with blood disorders. This includes new areas, as well as diseases where its medicines have already changed the standard of care, such as haemophilia A, diffuse large B-cell lymphoma (DLBCL) and follicu lar lymphoma (FL). These data also support Roche’s mission to dev...
Source: Roche Investor Update - November 2, 2023 Category: Pharmaceuticals Source Type: news

Episode 6: Fertility, Pregnancy and Chronic Myeloid Leukemia Episode 6: Fertility, Pregnancy and Chronic Myeloid Leukemia
Drs Michael J. Mauro and Jane F. Apperley answer key questions about pregnancy and family planning for patients diagnosed with chronic myeloid leukemia, including complications and treatment options.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 24, 2023 Category: Consumer Health News Tags: Hematology-Oncology InDiscussion Source Type: news

Episode 5: Monitoring and Diagnostics in Chronic Myeloid Leukemia Episode 5: Monitoring and Diagnostics in Chronic Myeloid Leukemia
Drs Michael J. Mauro and Jerald P. Radich discuss monitoring and diagnostics in chronic myeloid leukemia, including the Philadelphia chromosome and how it plays into the current treatment of CML.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 28, 2023 Category: Consumer Health News Tags: Hematology-Oncology InDiscussion Source Type: news

FDA Approves Bosutinib for Pediatric Patients with Chronic Myelogenous Leukemia
September 27, 2023 -- On September 26, 2023, the Food and Drug Administration approved bosutinib (Bosulif, Pfizer) for pediatric patients 1 year of age and older with chronic phase (CP) Ph+ chronic myelogenous leukemia (CML) that is newly diagnosed... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 27, 2023 Category: Drugs & Pharmacology Source Type: news